Literature DB >> 9302269

Abnormal FGFR 3 expression in cartilage of thanatophoric dysplasia fetuses.

A L Delezoide1, C Lasselin-Benoist, L Legeai-Mallet, P Brice, V Senée, A Yayon, A Munnich, M Vekemans, J Bonaventure.   

Abstract

Thanatophoric dysplasia (TD), the commonest lethal skeletal dysplasia in humans, is accounted for by recurrent mutations in the fibroblast growth factor receptor 3 gene (FGFR 3), causing its constitutive activation in vitro. Taking advantage of medical abortion of 18 TD fetuses, cartilage sections were studied for FGFR 3 gene expression by in situ hybridization and immunohistochemistry. Specific antibodies revealed high amounts of FGFR 3 in cartilage of TD fetuses with no increased level of the corresponding mRNA. The specific signal was mainly detected in the nucleus of proliferative and hypertrophic chondrocytes. Based on this observation and the abnormal expression of collagen type X in hypertrophic TD chondrocytes, we suggest that constitutive activation of the receptor through formation of a stable dimer increases its stability and promotes its translocation into the nucleus, where it might interfere with terminal chondrocyte differentiation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302269     DOI: 10.1093/hmg/6.11.1899

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  9 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

2.  FGF9 on the move.

Authors:  Douglas Spicer
Journal:  Nat Genet       Date:  2009-03       Impact factor: 38.330

3.  The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.

Authors:  E Monsonego-Ornan; R Adar; T Feferman; O Segev; A Yayon
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

4.  The endoplasmic reticulum stress transducer BBF2H7 suppresses apoptosis by activating the ATF5-MCL1 pathway in growth plate cartilage.

Authors:  Soutarou Izumi; Atsushi Saito; Soshi Kanemoto; Noritaka Kawasaki; Rie Asada; Hideo Iwamoto; Mami Oki; Hidetaka Miyagi; Mitsuo Ochi; Kazunori Imaizumi
Journal:  J Biol Chem       Date:  2012-08-30       Impact factor: 5.157

5.  The fibroblast growth factor receptor, FGFR3, forms gradients of intact and degraded protein across the growth plate of developing bovine ribs.

Authors:  Sujata G Pandit; Prasanthi Govindraj; Joachim Sasse; Peter J Neame; John R Hassell
Journal:  Biochem J       Date:  2002-01-15       Impact factor: 3.857

6.  Parathyroid hormone receptor type 1/Indian hedgehog expression is preserved in the growth plate of human fetuses affected with fibroblast growth factor receptor type 3 activating mutations.

Authors:  Sarah Cormier; Anne-Lise Delezoide; Catherine Benoist-Lasselin; Laurence Legeai-Mallet; Jacky Bonaventure; Caroline Silve
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

7.  Human osteogenesis involves differentiation-dependent increases in the morphogenically active 3' alternative splicing variant of acetylcholinesterase.

Authors:  D Grisaru; E Lev-Lehman; M Shapira; E Chaikin; J B Lessing; A Eldor; F Eckstein; H Soreq
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

8.  Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia.

Authors:  Jay Y Cho; Changsheng Guo; Monica Torello; Gregory P Lunstrum; Tomoko Iwata; Chuxia Deng; William A Horton
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

Review 9.  Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.

Authors:  Teresa Helsten; Maria Schwaederle; Razelle Kurzrock
Journal:  Cancer Metastasis Rev       Date:  2015-09       Impact factor: 9.264

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.